Literature DB >> 14657977

Aims, design and methods of the Smoking and Nicotine Dependence Awareness and Screening (SNICAS) study.

Stephan Muehlig1, Eva Hoch, Michael Hoefler, David Pittrow, Hans-Ulrich Wittchen.   

Abstract

The objectives of the Smoking and Nicotine Dependence Awareness (SNICAS) study are to provide nationally representative data on the prevalence of smoking and smoking dependence of primary care patients and the frequency in which smoking cessation interventions are offered and provided in primary care. With the inclusion of both providers' (doctor) and patients' perspectives, the study also attempts to identify the needs and motivational status for smoking cessation as reported by the patients and as perceived by the doctor. The Smoking and Nicotine Dependence Awareness study uses a two-stage epidemiological design. Stage 1 consists of a pre-study characterization of a nationwide sample of 889 primary care doctors (conservative response rate: 50%). Stage 2 consists of a cross-sectional assessment of unselected consecutive patients (n = 28,707, conservative response rate: 52.8%) on the study's target day, by means of patient questionnaire and a structured clinical appraisal of each patient by the doctor. This paper provides an overview of the design and methods of the study, informs about sampling and response rates, and examines whether the study sample could be considered representative of German primary care doctors.

Entities:  

Mesh:

Year:  2003        PMID: 14657977      PMCID: PMC6878365          DOI: 10.1002/mpr.158

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  35 in total

1.  [The German Health Survey. 1997/98].

Authors:  B M Bellach; H Knopf; W Thefeld
Journal:  Gesundheitswesen       Date:  1998-12

Review 2.  Pharmacotherapy of nicotine dependence.

Authors:  K O Haustein
Journal:  Int J Clin Pharmacol Ther       Date:  2000-06       Impact factor: 1.366

Review 3.  Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association.

Authors: 
Journal:  Am J Psychiatry       Date:  1996-10       Impact factor: 18.112

4.  Trends in cigarette smoking in the United States. Projections to the year 2000.

Authors:  J P Pierce; M C Fiore; T E Novotny; E J Hatziandreu; R M Davis
Journal:  JAMA       Date:  1989-01-06       Impact factor: 56.272

5.  Mortality by cause for eight regions of the world: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

6.  A comparison of sustained-release bupropion and placebo for smoking cessation.

Authors:  R D Hurt; D P Sachs; E D Glover; K P Offord; J A Johnston; L C Dale; M A Khayrallah; D R Schroeder; P N Glover; C R Sullivan; I T Croghan; P M Sullivan
Journal:  N Engl J Med       Date:  1997-10-23       Impact factor: 91.245

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

Review 8.  [Smoking cessation with the nicotine patch].

Authors:  A Batra; G Buchkremer
Journal:  Z Arztl Fortbild (Jena)       Date:  1995-10

Review 9.  Structure, content and reliability of the Munich-Composite International Diagnostic Interview (M-CIDI) substance use sections.

Authors:  G Lachner; H U Wittchen; A Perkonigg; A Holly; P Schuster; U Wunderlich; D Türk; E Garczynski; H Pfister
Journal:  Eur Addict Res       Date:  1998-03       Impact factor: 3.015

10.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation.

Authors:  C Silagy; D Mant; G Fowler; M Lodge
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

View more
  1 in total

1.  Smoking cessation in primary care - a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention.

Authors:  Hans-Ulrich Wittchen; Eva Hoch; Jens Klotsche; Stephan Muehlig
Journal:  Int J Methods Psychiatr Res       Date:  2011-03       Impact factor: 4.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.